Subsequently, we treated mouse models with PD-L1 monoclonal antibody therapy in conjunction with BCLAF1 inhibitors to explore the prospective therapeutic effects of anti-BCLAF1 in hepatocellular carcinoma. Here, CD274 is linked to hepatocellular carcinoma.